Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Hong I, Wan"'
Autor:
Min Li, Maria Jose Costa, Amy Chen, Danielle Fontaine, Bora Han, Emma RB Sangalang, Tiffany Chou, Mingrui An, Maja Bonacorsi, Hong I Wan, Pavel Strop
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/30e3c6502f914c4cad3f3c4ae4ae331e
Autor:
Tracy C. Kuo, Amy Chen, Ons Harrabi, Jonathan T. Sockolosky, Anli Zhang, Emma Sangalang, Laura V. Doyle, Steven E. Kauder, Danielle Fontaine, Sangeetha Bollini, Bora Han, Yang-Xin Fu, Janet Sim, Jaume Pons, Hong I. Wan
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-19 (2020)
Abstract Background Signal regulatory protein α (SIRPα) is a myeloid-lineage inhibitory receptor that restricts innate immunity through engagement of its cell surface ligand CD47. Blockade of the CD47–SIRPα interaction synergizes with tumor-spec
Externí odkaz:
https://doaj.org/article/aafee68f22694b6fb3c27f80eac48cb0
Autor:
Hyun Cheol Chung, Jeeyun Lee, Tracy C. Kuo, Won Seog Kim, Feng Jin, Sophia Randolph, Nehal Lakhani, Yung-Jue Bang, Rafael Santana-Davila, Philip Fanning, Wells A. Messersmith, Pierre Squifflet, Jaume Pons, Justin F. Gainor, Hong I. Wan, Keun-Wook Lee, Laura Q.M. Chow, F.S. Hodi, Patricia LoRusso
Publikováno v:
The Lancet Oncology. 22:1740-1751
Summary Background Both innate and adaptive immune responses are important components of anticancer immunity. The CD47–SIRPα interaction could represent an important pathway used by tumour cells to evade immune surveillance. We aimed to evaluate t
Autor:
Steven E Kauder, Tracy C Kuo, Ons Harrabi, Amy Chen, Emma Sangalang, Laura Doyle, Sony S Rocha, Sangeetha Bollini, Bora Han, Janet Sim, Jaume Pons, Hong I Wan
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0201832 (2018)
CD47 is a widely expressed cell surface protein that functions as an immune checkpoint in cancer. When expressed by tumor cells, CD47 can bind SIRPα on myeloid cells, leading to suppression of tumor cell phagocytosis and other innate immune function
Externí odkaz:
https://doaj.org/article/3ebc34039c37468dbf22b9ca99bbcb93
Publikováno v:
Transfusion. 60:2399-2407
ALX148, a novel CD47 blocking agent, is in clinical development for the treatment of advanced solid tumors and lymphoma. Because CD47 is highly expressed on red blood cells (RBCs), its therapeutic blockade can potentially interfere with pretransfusio
Autor:
Danielle Fontaine, Bora Han, Laura V. Doyle, Amy Y. Chen, Ons Harrabi, Hong I. Wan, Emma Sangalang, Janet Sim, Min Li, Jaume Pons, Tracy C. Kuo
Publikováno v:
Cancer Research. 81:1721-1721
Novel therapies capable of engaging both innate and adaptive immune responses may engender durable anti-tumor immunity. Activation of toll-like receptor 9 (TLR9) by unmethylated oligonucleotides promotes innate inflammatory responses and the inductio
Autor:
Hong I. Wan, Emma Sangalang, Tracy C. Kuo, Ons Harrabi, Laura Doyle, Janet Sim, Jaume Pons, Bora Han, Amy Y. Chen, Sangeetha Bollini, Sony S. Rocha, Steven E. Kauder
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0201832 (2018)
PLoS ONE
PLoS ONE
CD47 is a widely expressed cell surface protein that functions as an immune checkpoint in cancer. When expressed by tumor cells, CD47 can bind SIRPα on myeloid cells, leading to suppression of tumor cell phagocytosis and other innate immune function
Autor:
Sangeetha Bollini, Jaume Pons, Laura V. Doyle, Hong I. Wan, Ons Harrabi, Tracy C. Kuo, Steven E. Kauder, Emma Sangalang, Amy Y. Chen, Bora Han, Janet Sim
Publikováno v:
Cancer Research. 79:562-562
Targeting the CD47-SIRPα myeloid checkpoint pathway represents a novel therapeutic approach to enhance anti-cancer immunity. CD47 is a widely expressed cell surface protein that functions as a marker of self. Signal regulatory protein-α (SIRPα) is
Publikováno v:
Clinical and Translational Science. 2:242-247
With current national emphasis on translational research, data exchange systems are needed that bridge basic science and clinical research. To meet this challenge, an electronic system was developed by the Biomedical Informatics Unit (BMIU) of the Un
Publikováno v:
Drug Development Research. 70:60-69
Alzheimer's disease (AD) is a progressive neurodegenerative disease and the most common cause of age-related dementia. Currently available pharmacologic therapies, including acetylcholinesterase (AChE) inhibitors and N-methyl-D-aspartate (NMDA) recep